EPIX Deadline Today: Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of ESSA Pharma Inc. (NASDAQ: EPIX) securities between December 12, 2023 and October 31, 2024, inclusive (the 'Class Period'). The lawsuit describes ESSA as a 'clinical stage pharmaceutical company that focuses on the development of small molecular drugs for the treatment of prostate cancer.'
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that ESSA Pharma Inc. (NASDAQ: EPIX) Misled Investors Regarding its Business Operations.
According to the lawsuit, defendants, throughout the Class Period, failed to disclose to investors that: (1) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (2) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (3) the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint; (4) accordingly, defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against ESSA Pharma Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by March 25, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
Attorney Advertising. Prior results do not guarantee a similar outcome.
CONTACT: Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
[email protected]
SOURCE: The Rosen Law Firm, P.A.
Copyright Business Wire 2025.
PUB: 03/25/2025 11:18 AM/DISC: 03/25/2025 11:18 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Back to Basics for Activists: ICR Global Head of Governance Gabriel Hasson, Live at Nasdaq
CorpGov hosted a fireside chat on August 12 at Nasdaq MarketSite with Gabriel Hasson, Global Head of Governance and Shareholder Advisory, Managing Director at ICR. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed why activists are going back to basics and what it means in practice, what companies get consistently wrong about IPO prep, and the experience he brings to his new role at ICR. Watch the interview below, or click : About ICR Founded in 1998 by three former Wall Street analysts and lifelong collaborators, ICR was built to develop and deliver impactful strategic communications and advisory solutions for companies at every stage of growth. In the decades since, we've earned recognition globally for our expertise in public relations, investor relations, corporate and capital markets advisory solutions and our unparalleled ability to provide coordinated, sector-focused solutions to leaders in every industry for every complex scenario. More at About Gabriel Hasson Gabriel Hasson is the Global Head of Governance & Shareholder Advisory at ICR, where he helps companies navigate the intersection of corporate governance, shareholder engagement, and capital markets strategy. He advises boards and executives on assessing, improving, and communicating governance practices tied to material governance, environmental, and social risks and opportunities. His team also supports and executes shareholder engagement, helping clients build investor trust and respond to activism, M&A, and other high-stakes situations. Gabe has advised public companies and institutional investors on high-stakes shareholder matters including contested director elections, activism defense, executive compensation and equity plan scrutiny, board and leadership transitions, and proxy season preparation. His experience spans sectors such as healthcare, technology, energy, consumer goods, and financial services, with mandates covering Fortune 500 companies in the U.S. and Canada and leading issuers across Latin America and other emerging markets, particularly around governance, environmental, and social risks tied to long-term value creation. Prior to joining ICR, Gabe was an Investment Stewardship Director at BlackRock, overseeing a portfolio of over $400 billion across the U.S., Canada, and Latin America. Earlier, he was an M&A attorney advising global corporations on complex cross-border transactions and held senior roles at Institutional Shareholder Services (ISS) and Deloitte, where he counseled federal governments and Fortune 500 clients on shareholder engagement, corporate governance, sustainability, and stewardship priorities. Gabe holds a law degree from Universidad Panamericana, a certificate in U.S. Law from The George Washington Law School, a master's in international public policy from Johns Hopkins SAIS, and a certificate in corporate finance from Cornell University. Gabe currently serves on the Public Policy Committee of the International Corporate Governance Network (ICGN) and is an advisory board member of BH Compliance. READ MORE LA CorpGov Forum Sept 4: Featuring Sports, Entertainment & International Business Register for our weekly newsletter Contact:Click to follow us on LinkedIn The post Back to Basics for Activists: ICR Global Head of Governance Gabriel Hasson, Live at Nasdaq appeared first on CorpGov.
Business Wire
19 minutes ago
- Business Wire
PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ('Praxis' or 'the Company') (NASDAQ: PRAX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Praxis announced its Q2 2025 financial results on August 4, 2025. The Company reported mid-state clinical results from the trial of vormatrigine, an anti-seizure medication. The Company admitted that more than half of patients experienced treatment-emergent adverse events, with almost 25% of study participants discontinuing the medication. Based on this news, shares of Praxis fell more than 5% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
an hour ago
- Yahoo
Cisco fiscal Q4 results beat estimates, in-line guidance underwhelms
Cisco reported Wednesday fiscal fourth-quarter results that topoed estimates, but the network hardware supplier's in-line guidance for fiscal 2026 failed to impress investors. Cisco Systems Inc (NASDAQ:CSCO) fell more than 2% in recent afterhours trading Friday. For the three months ended Jul. 26, Cisco reported adjusted earnings per share of $0.99 on revenue of $14.76 billion, beating analyst estimates of $0.98 and $14.62B, respectively. Product revenue, which accounts for the bulk of overall revenue, rose 10% in the quarter year on year, while services was flat. For fiscal Q1, the company guided fiscal first-quarter adjusted EPS in a range of $0.97 to $0.99 on revenue of $14.65B to $14.85B, beating estimates for of $0.97 and $14.62B Looking further ahead to fiscal 2026, the company said it expects adjusted adjusted EPS in a range of $4.00 to $4.06 on revenue of $59B to $60B, compared with estimates of $4.03 and $59.55B. Related articles Cisco fiscal Q4 results beat estimates, in-line guidance underwhelms After soaring 149%, this stock is back in our AI's favor - & already +25% in July Apollo economist warns: AI bubble now bigger than 1990s tech mania Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
